Spots Global Cancer Trial Database for UMCC 2003-064 Resveratrol in Preventing Cancer in Healthy Participants

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: UMCC 2003-064 Resveratrol in Preventing Cancer in Healthy Participants

Official Title: Phase I Single-Dose Safety and Phamacokinetics Clinical Study of Resveratrol AKA IRB 2003-424

Study ID: NCT00098969

Conditions

Unspecified Adult Solid Tumor, Protocol Specific

Interventions

resveratrol

Study Description

Brief Summary: RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming, growing, or coming back. The use of resveratrol may prevent cancer. PURPOSE: This phase I trial is studying the side effects and best dose of resveratrol in preventing cancer in healthy participants.

Detailed Description: OBJECTIVES: * Determine the concentration of resveratrol and its metabolites in the plasma, urine, and feces of healthy participants. * Correlate dose with systemic concentration of this drug and its metabolites in these participants. * Determine the safety of this drug in these participants. OUTLINE: This is an open-label, dose-escalation, multicenter study. Beginning 5 days before study drug administration, participants are put on a controlled diet (avoiding all resveratrol-containing food or drink) for washout. Participants receive oral resveratrol once on day 1. Cohorts of 10 participants receive escalating doses of resveratrol until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 10 participants experience dose-limiting toxicity. A total of 16 participants are treated at the MTD. Participants are followed at 2 and 7 days. PROJECTED ACCRUAL: A total of 10-40 participants will be accrued for this study within 6 months.